Auxilium Pharma (AUXL) Misses Q1 EPS by 1c; Increases FY11 XIAFLEX Outlook
Tweet
Share
E-mailGet Alerts AUXL Hot Sheet
Join SI Premium – FREE
Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) reported Q1 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $58.4 million versus the consensus estimate of $61.13 million.
As a result of the $30 million in regulatory milestones received from Pfizer and the $15 million in milestones received from Asahi Kasei Pharma, the Company is increasing FY11 XIAFLEX contract and ex-U.S. revenues from the previously stated guidance of a range of $5 to $7 million to a range of $9 to $11 million.
As a result of the $30 million in regulatory milestones received from Pfizer and the $15 million in milestones received from Asahi Kasei Pharma, the Company is increasing FY11 XIAFLEX contract and ex-U.S. revenues from the previously stated guidance of a range of $5 to $7 million to a range of $9 to $11 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
